At the time of writing, TG Therapeutics Inc [TGTX] stock is trading at $35.53, down -4.62%. An important factor to consider is whether the stock is rising or falling in short-term value. The TGTX shares have lost -5.88% over the last week, with a monthly amount drifted -9.43%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on October 29, 2024, when TD Cowen initiated its Buy rating and assigned the stock a price target of $50. Previously, Goldman upgraded its rating to Neutral on August 02, 2023, and dropped its price target to $12. BofA Securities started tracking the stock assigning a Underperform rating and suggested a price target of $5 on May 20, 2022. B. Riley Securities reiterated its recommendation of a Buy and reduced its price target to $35 on February 23, 2022. Goldman downgraded its rating to Sell for this stock on November 15, 2021, and downed its price target to $26. In a note dated April 20, 2021, Goldman initiated an Neutral rating and provided a target price of $50 on this stock.
For the past year, the stock price of TG Therapeutics Inc fluctuated between $12.93 and $43.32. Currently, Wall Street analysts expect the stock to reach $27.5 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $35.53 at the most recent close of the market. An investor can expect a potential drop of -22.6% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
According to TG Therapeutics Inc [NASDAQ:TGTX], the company’s sales were 329.00M for trailing twelve months, which represents an 146.04% jump. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.12 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.98 points at the first support level, and at 32.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.98, and for the 2nd resistance point, it is at 40.42.
Ratios To Look Out For
It is important to note that TG Therapeutics Inc [NASDAQ:TGTX] has a current ratio of 6.25. On the other hand, the Quick Ratio is 5.03, and the Cash Ratio is 1.98. Considering the valuation of this stock, the price to sales ratio is 16.96, the price to book ratio is 24.90 and price to earnings (TTM) ratio is 254.51.
Transactions by insiders
Recent insider trading involved Power Sean A, CFO, that happened on Jan 03 ’25 when 11337.0 shares were sold. CFO, Power Sean A completed a deal on Jan 06 ’25 to sell 10021.0 shares. Meanwhile, Officer Power Sean A bought 10021.0 shares on Jan 06 ’25.
